Selected article for: "body weight and clinical dose"
Author: Kai Duan; Bende Liu; Cesheng Li; Huajun Zhang; Ting Yu; Jieming Qu; Min Zhou; Li Chen; Shengli Meng; Yong Hu; Cheng Peng; Mingchao Yuan; Jinyan Huang; Zejun Wang; Jianhong Yu; Xiaoxiao Gao; Dan Wang; Xiaoqi Yu; Li Li; Jiayou Zhang; Xiao Wu; Bei Li; Yanping Yu; Wei Chen; Yan Peng; Yeqin Hu; Lianzhen Lin; Xuefei Liu; Shihe Huang; Zhijun Zhou; Lianghao Zhang; Yue Wang; Zhi Zhang; Kun Deng; Zhiwu Xia; Qin Gong; Wei Zhang; Xiaobei Zheng; Ying Liu; Huichuan Yang; Dongbo Zhou; Ding Yu; Jifeng Hou; Zhengli Shi; Saijuan Chen; Zhu Chen; Xin-xin Zhang; Xiaoming Yang
Title: The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study
  • Document date: 2020_3_23
    • ID: 8znnq0rh_45
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03. 16.20036145 doi: medRxiv preprint antibodies can rapidly reduce the viral load and tends to improve clinical outcomes. The optimal dose and treatment time point, as well as the definite clinical benefits of CP therapy, need to be further investigated in randomized clinical studies. 2).Respiratory distress, RR ≥30 beats/min; 3).Oxygen s.....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03. 16.20036145 doi: medRxiv preprint antibodies can rapidly reduce the viral load and tends to improve clinical outcomes. The optimal dose and treatment time point, as well as the definite clinical benefits of CP therapy, need to be further investigated in randomized clinical studies. 2).Respiratory distress, RR ≥30 beats/min; 3).Oxygen saturation level less than 93% in resting state; 4). Partial pressure of oxygen (PaO2)/oxygen concentration (FiO2) ≤300 mmHg (1 mmHg=0.133 kPa). The exclusion criteria were as follows: 1). Previous allergic history to plasma or ingredients (Sodium Citrate); 2). Cases with serious general conditions, such as severe organ donor depending on the age and body weight, and each sample was divided and stored as 200 mL aliquots at 4℃ without any detergent or heat treatment. The CP was then treated with methylene blue and light treatment for 30 minutes in the medical plasma virus inactivation cabinet (Shandong Zhongbaokang Medical Appliance Co., Ltd).

    Search related documents:
    Co phrase search for related documents
    • allergic history and clinical study: 1, 2
    • allergic history and CP therapy: 1
    • body age and clinical benefit: 1, 2, 3, 4, 5, 6, 7
    • body age and clinical outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • body age and clinical study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical benefit and CP therapy: 1, 2, 3, 4, 5, 6
    • clinical benefit and CP therapy clinical benefit: 1, 2, 3
    • clinical benefit and optimal dose: 1, 2, 3, 4, 5, 6
    • clinical outcome and CP therapy: 1, 2, 3, 4, 5, 6, 7, 8
    • clinical outcome and exclusion criterion: 1, 2
    • clinical outcome and general condition: 1, 2, 3, 4
    • clinical outcome and medical plasma: 1, 2
    • clinical outcome and optimal dose: 1, 2, 3, 4, 5
    • clinical outcome improve and CP therapy: 1, 2
    • clinical study and CP therapy: 1, 2, 3, 4
    • clinical study and exclusion criterion: 1
    • clinical study and general condition: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • clinical study and medical plasma: 1
    • clinical study and mL aliquot: 1, 2